Early Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of STR-P005 | MicrobiomeTrials← Back to trialsNCT07655453
Early Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of STR-P005
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2026-08-01Est. Completion: 2027-07-30
Enrollment target: 36 participants Other microbiome trials you might be interested in
Systemic Lupus ErythematosusLupus Nephritis
Systemic lupus erythematosus (SLE) is the most common systemic autoimmune disease in China. The kidneys are the organ mo…
Nanjing, ChinaCompleted Jan 2028
Autoimmune Hemolytic Anemia (AIHA)
1. wAIHA Treatment Regimen: Group A (50mg group): Orelabrutinib 50 mg, orally, once daily. After 4 weeks of treatment, i…
Beijing, ChinaEst. completion Mar 1, 2027